Employing a PLGA-TPGS based nanoparticle to improve the ocular delivery of Acyclovir

Agrahari, 2016, A comprehensive insight on ocular pharmacokinetics, Drug Deliv. Transl. Res., 6, 735, 10.1007/s13346-016-0339-2 Akhter, 2013, Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits, Eur. J. Nanomed., 5, 159, 10.1515/ejnm-2013-0012 Alshamsan, 2014, Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles, Saudi Pharmaceut. J., 22, 219, 10.1016/j.jsps.2013.12.002 Attama, 2008, Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct, Int. J. Pharm., 355, 307, 10.1016/j.ijpharm.2007.12.007 Bala, 2004, PLGA nanoparticles in drug delivery: the state of the art, Crit. Rev. Ther. Drug Carrier Syst., 21, 387, 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20 Bergstrom, 2003, Absorption classification of oral drugs based on molecular surface properties, J. Med. Chem., 46, 558, 10.1021/jm020986i Bhosale, 2011, Formulation and optimization of mucoadhesive nanodrug delivery system of acyclovir, J. Young Pharm., 3, 275, 10.4103/0975-1483.90236 Chen, 2011, Oral delivery of DMAB-modified docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy, Nanoscale Res. Lett., 6, 4, 10.1007/s11671-010-9741-8 Cholkar, 2013, Novel strategies for anterior segment ocular drug delivery, J. Ocul. Pharmacol. Ther., 29, 106, 10.1089/jop.2012.0200 Cohen, 2012, Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis, Ophthalmology, 119, 66, 10.1016/j.ophtha.2011.07.006 Collnot, 2010, Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access, Mol. Pharm., 7, 642, 10.1021/mp900191s Craig, 1995, Refractive index and osmolality of human tears, Optom. Vis. Sci., 72, 718, 10.1097/00006324-199510000-00004 Danhier, 2012, PLGA-based nanoparticles: an overview of biomedical applications, J. Control. Release, 161, 505, 10.1016/j.jconrel.2012.01.043 De, 2004, Particle size and temperature effect on the physical stability of PLGA nanospheres and microspheres containing Bodipy, AAPS PharmSciTech, 5, e53, 10.1208/pt050453 Diebold, 2007, Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP), Biomaterials, 28, 1553, 10.1016/j.biomaterials.2006.11.028 Dintaman, 1999, Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS), Pharm. Res., 16, 1550, 10.1023/A:1015000503629 Djebli, 2017, Ocular drug distribution after topical administration: population pharmacokinetic model in rabbits, Eur. J. Drug Metab. Pharmacokinet., 42, 59, 10.1007/s13318-016-0319-4 Draize, 1944, Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes, J. Pharmacol. Exp. Ther., 82, 377 du Toit, 2011, Ocular drug delivery – a look towards nanobioadhesives, Expert Opin. Drug Deliv., 8, 71, 10.1517/17425247.2011.542142 Fabiano, 2015, Mucoadhesive nano-sized supramolecular assemblies for improved pre-corneal drug residence time, Drug Dev. Ind. Pharm., 41, 2069, 10.3109/03639045.2015.1066798 Fangueiro, 2014, Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation, Colloids Surf. B Biointerfaces, 123, 452, 10.1016/j.colsurfb.2014.09.042 Grenha, 2007, Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization, Biomacromolecules, 8, 2072, 10.1021/bm061131g Hotujac Grgurevic, 2017, Tear fluid-eye drops compatibility assessment using surface tension, Drug Dev. Ind. Pharm., 43, 275, 10.1080/03639045.2016.1238924 Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials, 21, 2475, 10.1016/S0142-9612(00)00115-0 Kalam, 2016, Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone, Int. J. Biol. Macromol., 89, 127, 10.1016/j.ijbiomac.2016.04.070 Kalam, 2016, The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone, Int. J. Biol. Macromol., 89, 559, 10.1016/j.ijbiomac.2016.05.016 Kasim, 2004, Molecular properties of WHO essential drugs and provisional biopharmaceutical classification, Mol. Pharm., 1, 85, 10.1021/mp034006h Law, 2000, Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption, J. Control. Release, 63, 135, 10.1016/S0168-3659(99)00192-3 Lim, 2014, Common eye drops and their implications for pH measurements in the management of chemical eye injuries, Int. J. Ophthalmol., 7, 1067 Ma, 2010, Nanoparticles of poly(lactide-co-glycolide)-d-a-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment, Nanoscale Res. Lett., 5, 1161, 10.1007/s11671-010-9620-3 McCall, 2013, PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS, J Vis, Exp, 51015 Naderkhani, 2014, Improved permeability of acyclovir: optimization of mucoadhesive liposomes using the phospholipid vesicle-based permeation assay, J. Pharm. Sci., 103, 661, 10.1002/jps.23845 Nagarwal, 2009, Polymeric nanoparticulate system: a potential approach for ocular drug delivery, J. Control. Release, 136, 2, 10.1016/j.jconrel.2008.12.018 Parr, 2016, The effect of excipients on the permeability of BCS Class III compounds and implications for biowaivers, Pharm. Res., 33, 167, 10.1007/s11095-015-1773-4 Salama, 2015, A novel method for preparing surface-modified fluocinolone acetonide loaded PLGA nanoparticles for ocular use vitro and in vivo evaluations, AAPS PharmSciTech, 17, 1159, 10.1208/s12249-015-0448-0 Santander-Ortega, 2007, Stability and physicochemical characteristics of PLGA, PLGA:poloxamer and PLGA:poloxamine blend nanoparticles: a comparative study, Colloids Surf., A, 296, 132, 10.1016/j.colsurfa.2006.09.036 Seyfoddin, 2010, Solid lipid nanoparticles for ocular drug delivery, Drug Deliv., 17, 467, 10.3109/10717544.2010.483257 Shen, 2014, Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown, Invest. Ophthalmol. Vis. Sci., 55, 1056, 10.1167/iovs.13-13650 Silva, 2013, Analysis of acyclovir in vitreous humor by a validated HPLC method, Pharmazie, 68, 235 Singh, 2011, Medical management of glaucoma: principles and practice, Indian J. Ophthalmol., 59, S88, 10.4103/0301-4738.73691 Stulzer, 2008, Development and validation of an RP-HPLC method to quantitate acyclovir in cross-linked chitosan microspheres produced by spray drying, J. Chromatogr. Sci., 46, 496, 10.1093/chromsci/46.6.496 Tiffany, 1989, Tear film stability and tear surface tension, Curr. Eye Res., 8, 507, 10.3109/02713688909000031 Troy, 2006 USP, 2016 Warsi, 2014, Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits, Colloids Surf., B, 122, 423, 10.1016/j.colsurfb.2014.07.004 Wu, 2005, Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharm. Res., 22, 11, 10.1007/s11095-004-9004-4 Yu, 1999, Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability, Pharm. Res., 16, 1812, 10.1023/A:1018939006780 Zhang, 2010, PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel, Comput. Methods Programs Biomed., 99, 306, 10.1016/j.cmpb.2010.01.007 Zhang, 2006, The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles, Biomaterials, 27, 4025, 10.1016/j.biomaterials.2006.03.006 Zhang, 2008, In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy, Pharmaceut. Res., 25, 1925, 10.1007/s11095-008-9611-6 Zimmer, 1995, Microspheres and nanoparticles used in ocular delivery systems, Adv. Drug Deliv. Rev. Ocular Drug Deliv., 16, 61, 10.1016/0169-409X(95)00017-2